PRUNUS Therapeutics discovers and develops innovative therapeutics for human and animal healthcare. PRUNUS’ main platform focuses on an innovative cancer therapy that harnesses the power of self–immune system to find and reject cancer cells.
Targeted Neoantigen Loading – Selectively loading a foreign immugenic molecule into cancer cells. The approach takes advantage of puromycin-based prodrug technology to selectively mark a broad spectrum of cancer cells with a small tag (neoantigen). The neoantigen triggers the immune system to recognize and reject them as “red-flagged invaders” like bacteria or viruses.
Proof-of-Concept / Pre-Clinical Development
- Small Molecules